Singapore markets close in 6 hours 5 minutes

electroCore, Inc. (ECOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.2600+0.3000 (+15.31%)
At close: 4:00PM EDT

2.1100 -0.15 (-6.64%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close1.9600
Bid2.1100 x 2200
Ask2.1500 x 4000
Day's range2.0100 - 2.3500
52-week range0.3200 - 5.6400
Avg. volume5,559,989
Market cap86.174M
Beta (5Y monthly)2.05
PE ratio (TTM)N/A
EPS (TTM)-1.3310
Earnings date11 Nov 2020 - 16 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.83
  • GlobeNewswire

    electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

    BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ ( beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time. Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.

  • ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates

    ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates

    electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    electroCore Announces First Quarter Financial Results

    BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.